🇺🇸 FDA
Pipeline program

LBT-3627

LBT-3627-101

Phase 1 small_molecule active

Quick answer

LBT-3627 for Parkinson Disease is a Phase 1 program (small_molecule) at Biotech Pharmaceutical Co., with 1 ClinicalTrials.gov record(s).

Program details

Company
Biotech Pharmaceutical Co.,
Indication
Parkinson Disease
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials